Phase 3 trials are ongoing, and without completed large-scale safety and efficacy data, the compound cannot be considered ready for routine clinical use
While this may not be true for EACH and EVERY person, its still worth considering
By 104 weeks, approximately 77% of SELECT patients on dose were receiving the target semaglutide 2.4 mg weekly dose, which is lower than the corresponding proportion of patients in STEP 1 (89.6% were receiving the target dose at week 68) 14,21
While it can help the body burn fat, its not suitable for everyone
Metabolic disturbances : Excessive lipolysis may theoretically elevate free fatty acids, potentially affecting liver function or lipid profiles, though this has not been studied in this context